analyzing-russian-media-outlets-and-telegram-interaction

training-unbiased-diffusion-models-from-biased-datasets-a-time-dependent-approach

covid-domain의-기계-번역-loresmt-2021의-영어-아일랜드-사례-연구

die-doppelte-kante-von-retrieval-augmentierten-chatbots

선박-궤적-계획-및-행동-생성에-적용된-빠르게-탐색하는-무작위-트리-알고리즘의-비교-연구

동물-친화적-ai에-대한-주장

maschinenübersetzung-im-covid-bereich-eine-englisch-irische-fallstudie-für-loresmt-2021

nested-dirichlet-models-for-unsupervised-attack-pattern-detection-in-honeypot-data


Trazodone, dibenzoylmethane, and tauroursodeoxycholic acid do not prevent motor dysfunction and neurodegeneration in a mouse model of Marinesco-Sjögren syndrome.


coremsg

There is no cure for Marinesco-Sjögren syndrome (MSS), a genetic multisystem disease linked to loss-of-function mutations in the SIL1 gene, encoding a BiP co-chaperone. We previously found that the PERK kinase inhibitor GSK2606414 delayed cerebellar Purkinje cell (PC) degeneration and the onset of ataxia in the woozy mouse model of MSS. However, GSK2606414 is toxic to the pancreas and does not completely rescue the woozy phenotype. The present study tested trazodone and dibenzoylmethane (DBM), which partially inhibit PERK signaling with neuroprotective effects and no pancreatic toxicity. We also tested the chemical chaperone tauroursodeoxycholic acid (TUDCA), which can protect MSS patients’ cells from stress-induced apoptosis. Mice were chronically treated for five weeks, starting from a presymptomatic stage. Trazodone was given 40 mg/kg daily by intraperitoneal (ip) injection. DBM was given 0.5% in the diet ad libitum. TUDCA was given either 0.4% in the diet, or 500 mg/kg ip every three days. None of the treatments prevented motor dysfunction in woozy mice, assessed by the beam walking and rotarod tests. Only trazodone slightly boosted beam walking performance. However, immunohistochemistry found no reduction in the number of CHOP-positive PCs, or increased PC survival, indicating no neuroprotective inhibition of PERK signaling. Pharmacokinetic studies excluded that the lack of effect was due to altered drug metabolism in woozy mice. These results indicate that trazodone, DBM and TUDCA, at dosing regimens active in other neurodegenerative disease mouse models, have no disease-modifying effect in a preclinical model of MSS.

### Competing Interest Statement

The authors have declared no competing interest.

Trazodone, dibenzoylmethane and tauroursodeoxycholic acid do not prevent motor dysfunction and neurodegeneration in Marinesco-Sjögren syndrome mice

lack-of-therapeutic-efficacy-of-trazodone-dibenzoylmethane-and-tauroursodeoxycholic-acid-in-a-mouse-model-of-marinesco-sjögren-syndrome


Lack of Therapeutic Efficacy of Trazodone, Dibenzoylmethane, and Tauroursodeoxycholic Acid in a Mouse Model of Marinesco-Sjögren Syndrome


title_rewrite

Pharmacological interventions for Marinesco-Sjögren syndrome